Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada

Executive Summary

• Fennec Pharmaceuticals closed a non‑brokered offering of its common shares in Canada at US $7.50 per share, raising gross proceeds of US $5.025 million.
• The shares were sold to existing institutional shareholders under the listed issuer financing exemption; no hold period applies under Canadian securities law.
• Proceeds are intended to support ongoing corporate activities, including commercialization of PEDMARK®/PEDMARQSI® and further development initiatives.

Key Details

• Offering Size: US $5,025,000 gross proceeds.
• Share Price: US $7.50 per common share.
• Investor Base: Existing institutional shareholders; purchasers resident in any Canadian province except Quebec.
• Exemption Used: Listed issuer financing exemption under Part 5A of National Instrument 45‑106 (Prospectus Exemptions).
• Regulatory Treatment: Shares not subject to a hold period under applicable Canadian securities laws; registered in the U.S. pursuant to a prospectus supplement and accompanying prospectus.
• Use of Proceeds: Not explicitly detailed in release – generally to fund corporate operations, product commercialization (PEDMARK®/PEDMARQSI®), and further development activities.
• Related Documents: Offering document available at www.sedarplus.com and www.fennecpharma.com; investors advised to review before investing.

Notable Quotes

(No direct quotes from executives were included in the release.)